The trajectory of Viagra presents a nuanced case for investors in the pharmaceutical sector. While initially a blockbuster success, creating huge profits, the patent expiration and the subsequent flood of generic versions have drastically changed income. This raises questions about the ongoing sustainability of related therapeutic innovations and s